摘要
目的:评价低于标准剂量的重组组织型纤溶酶原激活剂(rt-PA)治疗急性缺血性脑卒中的疗效。方法:60例急性缺血性脑卒中患者随机分为2组,各30例。患者均于发病后4.5h内给予rt-PA进行溶栓治疗,将低于标准剂量的习惯剂量(0.6mg·kg-1,最大剂量60mg)设为观察组,指南推荐剂量(0.9mg·kg-1,最大剂量90mg)设为对照组。溶栓前、溶栓后4周及治疗2个月后根据中国脑卒中临床神经功能缺损程度评分量表(CSS)对患者的脑功能进行评分,依评分结果判断疗效。结果:溶栓前2组CSS评分比较差异无统计学意义(P>0.05);溶栓后4周2组CSS评分比较差异也无统计学意义(P>0.05);溶栓前与溶栓后4周比较,观察组与对照组CSS评分差异均有统计学意义(P<0.05和P<0.01)。观察组与对照组治疗2个月后有效率分别为86.7%、90.0%(P>0.05)。结论:应用低于标准剂量的rt-PA治疗急性缺血性脑卒中,能收到和标准剂量相同的疗效。
OBJECTIVE:To evaluate the clinical effect of low-dose recombinant tissue plasminogen activator (rt-PA) in the treatment of acute ischemic stroke.METHODS:60 patients with acute ischemic stroke were recruited and randomly divided into 2 groups with 30 cases in each group.All patients were given rt-PA within 4.5 h.The observation group were treated with rt-PA 0.6 mg·kg-1 (maximum dose of 60 mg) and the control group were treated with 0.9 mg·kg-1 (maximum dose of 90 mg).The cerebral function of patients were evaluated according to CSS before treatment,four weeks and two months after treatment,and then therapeutic efficacy was evaluated.RESULTS:There was no statistical significance in the difference of CSS score between 2 groups before treatment and 4 weeks after treatment (P〉0.05).Before and 4 weeks after treatment,the CSS scores in the observation group and the control group were significantly different (P0.05).CONCLUSION:The therapy of low-dose rt-PA obtains same therapeutic efficacy as standard dose for acute ischemic stroke.
出处
《中国药房》
CAS
CSCD
2012年第22期2067-2069,共3页
China Pharmacy